Cervical cancer screening and prevention in low-resource settings

Clinical Obstetrics and Gynecology

Volumn 56, Issue 1, 2013, Pages 76-87

  Bradford, Leslie ^a   Goodman, Annekathryn ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

cervical cancer; developing countries; HPV DNAtesting; low resource setting; screening; VIA

Indexed keywords

ACETIC ACID; HPV 007; UNCLASSIFIED DRUG;

CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; CONFERENCE PAPER; DEVELOPING COUNTRY; DIAGNOSTIC ACCURACY; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INTERMETHOD COMPARISON; LOWEST INCOME GROUP; META ANALYSIS (TOPIC); PAPANICOLAOU TEST; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER;

ACETIC ACID; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84873408431     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31828237ac     Document Type: Conference Paper

References (73)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBO-CAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Levine LD, Chudnoff SG, Taylor K, et al. 5-day educational program for teaching cervical cancer screening using visual inspection with acetic acid in low-resource settings. Int J Gynaecol Obstet. 2011;115:171-174.
3. Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents Vol. IX. 2007 ed. Lyon, France: IARC Scientific Publications; 2007. IARC Cancer Base No. 160.
4. Valsecchi MG, Steliarova-Foucher E. Cancer registration in developing countries: luxury or necessity? Lancet. 2008;9:159-167.
5. Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer. 2006;6: 603-612.
6. Bruni L, Diaz M, Castellsague X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202: 1789-1799.
7. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30, 848 inva-sive cervical cancers worldwide: variation by geo-graphical region, histological type and year of publication. Int J Cancer. 2011;128:927-935.
8. Paavonen J, Naud P, Salmeron J, et al. HPV PATRICIA Study Group Efficacy of human pap-illomavirus (HPV)-16/18 AS04-adjuvanted vac-cine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis ofadouble-blind, randomised study in young women. Lancet. 2009;374:301-314.
9. The FUTURE II Study Group Quadrivalent vac-cine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
10. Goldie SJ, O'Shea M, Diaz M, et al. Benefits, cost requirements and cost-effectiveness of the HPV16, 18 vaccine for cervical cancer prevention in developing countries: policy implications. Re-prodHealth Matters. 2008;16:86-96.
11. Diaz M, Kim JJ, Albero G, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Can-cer. 2008;99:230-238.
12. The Glaxo Smith Kline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04 adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years. Lancet. 2009;12:1975-1985.
13. Wright TC Jr, Kuhn L. Alternative approaches to cervical cancer screening for developing countries. Best Pract Res Clin Obstet Gynaecol. 2012;26:197-208.
14. Suba EJ, Murphy SK, Donnelly AD, et al. Sys-tems analysis of real-world obstacles to successful cervical cancer prevention in developing coun-tries. Am JPublic Health. 2006;96:480-487.
15. Benoit AG, Krepart GV, Lotocki RJ. Results of prior cytologic screening in patients with a diag-nosis of Stage I carcinoma of the cervix. Am J Obstet Gynecol. 1984;148:690-694.
16. Soost HJ, Lange HJ, Lehmacher W, et al. The validation ofcervical cytology. Sensitivity, specific-ityandpredictivevalues. Acta Cytol. 1991;35:8-14.
17. Renshaw AA. Measuring sensitivity in gyn-ecologic cytology: a review. Cancer. 2002;96: 210-217.
18. Brewster WR, Hubbell FA, Largent J, et al. Fea-sibility of management of high-grade cervical lesions in a single visit: a randomized controlled trial. JAMA. 2005;294:2182-2187.
19. University of Zimbabwe/JHPIEGO Cervical Cancer Project Visual inspection with acetic acid for cervical cancer screening: test qualities in a primary-care setting. Lancet. 1999;353:869-873.
20. Denny L, Kuhn L, Pollack A, et al. Evaluation of alternative methods ofcervical cancer screening in resource poor settings. Cancer. 2000;89:826-833.
21. Wright TC Jr, Denny L, Kuhn L, et al. HPV DNA testing ofself-collected vaginal samples compared with cytologic screening to detect cervical cancer (comment). JAMA. 2000;283:81-86.
22. Denny L, Kuhn L, Pollack A, et al. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer. 2002;94:1699-1707.
23. Cronje HS, Parham GP, Cooreman BF, et al. A comparison offour screening methods for cervical neoplasia in a developing country. Am J Obstet Gynecol. 2003;188:395-400.
24. Sankaranarayanan R, Thara S, Anjali S, et al. Accuracy ofconventional cytology: results from a multicentre screening study in India. J Med Screen. 2004;11:77-84.
25. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141: 680-689.
26. Nanda K, McCrory DC, Myers ER, et al. Accu-racy of the papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132: 810-819.
27. Suba EJ, Nguyen CH, Nguyen BD, et al. Viet/American cervical cancer prevention project. De novo establishment and cost-effectiveness of pa-panicolaou cytology screening services in The Socialist Republic ofVietnam. Cancer. 2001;91: 928-939.
28. Suba EJ, Raab SS. Lessons learned from success-ful Papanicolaou cytology cervical cancer preven-tion in The Socialist Republic ofVietnam. Diagn Cytopathol. 2012;40:355-366.
29. Hassan N. The Cervi Cusco Project. ASCBulletin. 2010;47:154-156.
30. Schiller W. Early diagnosis of carcinoma of the cervix. Surg Gynaecol Obstet. 1933;56:210-222.
31. Belinson JL, Pretorius RG, Zhang WH, et al. Cervical cancer screening by simple visual inspec-tion after acetic acid. Obstet Gynecol. 2001;98: 441-444.
32. Gontijo RC, Derchain SFM, Montemor EB, et al. Pap smear, hybrid capture II, and visual inspec-tion in screening for uterine cervical lesions. Cad Saude Publica. 2005;21:141-149.
33. Braganca JF, Derchain SFM, Sarian LO, et al. Aided visual inspection with acetic acid (VIA) and HPV detection as optional screening tools for cervical cancer and its precursor lesions. Clin Exp Obstet Gynecol. 2005;32:225-229.
34. Nessa A, Hussain MA, Rahman JN, et al. Screen-ing for cervical neoplasia in Bangladesh using visual inspection with acetic acid. Int J Gynecol Obstet. 2010;111:115-118.
35. Ngoma T, Muwonge R, Mwaiselage J, et al. Evaluation ofcervical visual inspection screening in Dar es Salaam, Tanzania. IJ Gynecol Obstet. 2010;109:100-104.
36. Muwonge R, Manuel MG, Filipe AP, et al. Visual screening for early detection ofcervical neoplasia in Angola. Int J Gynecol Obstet. 2010;111:68-72.
37. Gaffikin L, Lauterbach M, Blumenthal PD. Per-formance of visual inspection with acetic acid for cervical cancer screening: a qualitative summary ofevidence to date. Obstet Gynecol Surv. 2003;58: 543-550.
38. Arbyn M, Sankaranarayanan R, Muwonge R, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer. 2008;123:153-160.
39. Sauvaget C, Fayette JM, Muwonge R, et al. Ac-curacy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet. 2011;113:14-24.
40. Sankaranarayanan R, Nessa A, Esmy PO, et al. Visual inspection methods for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol. 2012;26:221-232.
41. Basu P, Nessa A, Majid M, et al. Evaluationofthe National Cervical Cancer Screening Programme of Bangladesh and the formulation of quality assurance guidelines. J Fam Plann Reprod Health Care. 2010;36:131-134.
42. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385-1394.
43. Davis-Dao CA, Cremer M, Felix J, et al. Effect of cervicitis on visual inspection with acetic acid. J Low Genit Tract Dis. 2008;12:282-286.
44. Sun ZC, Cui Y, Yang L, et al. Study on the prevalence of reproductive tract infections and influencing factors on women in rural areas of the Middle and Western regions in China. Zhong-hua Liu Xing Bing Xue Za Zhi. 2010;31:961-964.
45. Pacarada M, Lulaj S, Kongjeli G, et al. Factors associated with pathologic colposcopic and cytologic changes in 500 clinically asymptomatic women. Int J Gynaecol Obstet. 2010;108:7-11.
46. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavi-rus infection. NEngl JMed. 1992;327:1272-1278.
47. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000;9:945-951.
48. Franco EL. Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monographs. 2003;31:89-96.
49. Womack SD, Chirenje ZM, Blumenthal PD, et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. Br J Obstet Gynecol. 2000;107:33-38.
50. Sankaranarayanan R, Chatterji R, Shastri S, et al. Accuracy of human papillomavirus testing in the primary screening of cervical neoplasia: results from a multicentre study in India. Int J Cancer. 2004;112:341-347.
51. Ogilvie GS, Patrick DM, Schulzer M, et al. Diag-nostic accuracy ofselfcollected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect. 2005;81: 207-212.
52. Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low resource settings. JAMA. 2001;285:3107-3115.
53. Parkin DM, Nambooze S, Wabwire-Mangen F, et al. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int J Cancer. 2010;126: 1187-1195.
54. Mitchell S, Ogilvie G, Steinberg M, et al. Assess-ing women's willingness to collect their own cervical samples for HPV testing as part of the ASPIRE cervical cancer screening project in Uganda. Int J Gynaecol Obstet. 2011;114: 111-115.
55. Knowles L, Ogilvie GS, Taylor D, Outcomes of a social networking approach (SNA) to syphilis case finding in a Street Nurse Program: improved case finding and contact identification. 2nd Inter-national Conference on Urban Health, New York, NY, 2003.
56. Dzuba IG, Diaz EY, Allen B, et al. The accept-ability of self-collected samples for HPV testing vs. the pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med. 2002;11:265-275.
57. Tisci S, Shen YH, Fife D, et al. Patient acceptance of self-sampling for human papillomavirus in rural China. J Low Genit Tract Dis. 2003;7: 107-116.
58. Smith K, Harrington K, Wingood G, et al. Self-obtained vaginal swabs for diagnosis of treat-able sexually transmitted diseases in adolescent girls. Arch Pediatr Adolesc Med. 2001;155: 676-679.
59. Qiagen. Expanding access to cervical cancer screening, 2009. Available at: http://www.qiagen. com/about/whoweare/qiagencares/the-carehpv-test. pdf. Accessed May 20, 2012.
60. Zhao FH, Lin MJ, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled anal-ysis of individual patient data from 17 popula-tion-based studies from China. Lancet Oncol. 2010;11:1160-1171.
61. Denny L, Kuhn L, De Souza M, et al. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAm Med Assoc. 2005;294:2173-2181.
62. Denny L, Kuhn L, Hu CC, et al. Human papil-lomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. JNCI Cancer Spectrum. 2010;102:1557-1567.
63. Flores YN, Bishai DM, Lorincz A, et al. HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mex-ico. CCC. 2011;22:261-272.
64. Salmeron J, Lazcano-Ponce E, Lorincz A, et al. Comparison of HPV-based assays with Papani-colaou smears for cervical cancer screening in Morelos State, Mexico. CCC. 2003;14:505-512.
65. Shi JF, Canfell K, Lew JB, et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effec-tiveness modeling study. BMC Cancer. 2011; 11:239.
66. Sherris J, Wittet S, Kleine A, et al. Evidence-based, alternative cervical cancer screening ap-proaches in low-resource settings. Int Perspect Sex Reprod Health. 2009;35:147-154.
67. Gaffikin L, Blumenthal PD, Emerson M, et al. Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project. Lancet. 2003;361:814-820.
68. Kalliala I, Nieminen P, Dyba T, et al. Cancer free survival after CIN treatment: comparisons of treatment methods and histology. Gynecol Oncol. 2007;105:228-233.
69. Ferenczy A. Comparison of cryo-and carbon dioxide laser therapy for cervical intraepithelial neoplasia. Obstet Gynecol. 1985;66:793-798.
70. Castro W, Gage JC, Gaffikin L, et al. Effective-ness, Safety, and Acceptability ofCryotherapy: A Systematic Literature Review. Seattle, WA: PATH; 2003.
71. Denny L, Kuhn L, Risi L, et al. Two-stage cervical cancer screening: an alternative for resource-poor settings. Am J Obstet Gynecol. 2000;183: 383-388.
72. World Health Organization, International Agency for Research on Cancer-IARC WHO: IARC working group on evaluation of cervical cancer screening programmes. Screening for squ-amous cervical cancer: duration of low risk after negative results of cervical cytology and its impli-cation for screening policies. BMJ. 1986;293: 659-664.
73. Alliance for Cervical Cancer Prevention. Recent Evidence on Cervical Cancer Screening in Low-Resource Settings. Seattle, WA: Alliance for Cervical Cancer Prevention; 2011